Navigation Links
ACTOplus met® XR (pioglitazone HCl and metformin HCl extended-release) Now Available in Pharmacies Nationwide
Date:6/21/2010

DEERFIELD, Ill., June 21 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. announced today that ACTOplus met® XR, an extended-release version of the combination medication ACTOplus met® (pioglitazone HCl and metformin HCl), is now available in United States (U.S.) pharmacies for the treatment of type 2 diabetes as an adjunct to diet and exercise. This once-daily prescription medication, available in two commonly used dosages of pioglitazone and metformin XR – 15 mg/1000 mg and 30 mg/1000 mg tablets – is the first and only oral antidiabetic fixed-dose combination medication with the extended-release formulation of metformin.

ACTOplus met XR combines ACTOS® (pioglitazone HCL) and metformin, two widely used diabetes medications with established safety profiles, in a single tablet. ACTOS directly targets insulin resistance, a condition in which the body does not efficiently use the insulin it produces, and metformin acts primarily by reducing the amount of glucose produced in the liver. These medications work in combination, along with diet and exercise, to help patients with type 2 diabetes improve glycemic control.

Takeda is the inventor and developer of ACTOS, which was launched commercially in the U.S. in 1999. ACTOS has been an effective and appropriate treatment for people living with type 2 diabetes, and has been prescribed for more than 10 million patients to date.

Extended-release metformin, one of the active ingredients in ACTOplus met XR, was developed by Watson Laboratories, a subsidiary of Watson Pharmaceuticals, Inc. and licensed to Takeda Pharmaceutical Company Limited.

ACTOplus met® (pioglitazone HCl and metformin HCl) <
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
2. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
3. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
4. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
5. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
6. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
7. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
8. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
9. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
10. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
11. Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oregon , October 22, 2014 ... "Global Disposable Gloves Market (Product type, Form, End user, ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... global disposable gloves market. Based on key trends tracked, ... be valued at $7.9 billion by 2020, registering a ...
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)... WESTMINSTER, Colo. , Oct. 22, 2014   ... class of infusion systems designed to maximize targeted delivery ... is pleased to announce that oncologist John R. ... Norris Comprehensive Cancer Center, and surgical oncologist Steven ... Center have joined the Company,s Scientific Advisory Board (SAB).  ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... /PRNewswire/ -- A new study suggests,strong variation in ... U.S. Anaphylaxis is a severe allergic,reaction that can ... differences in EpiPen prescribing, a marker of,anaphylaxis risk, ... low levels of vitamin D,from lack of sunshine, ...
... Journal of the,American Society of Clinical Oncology has ... by Dr. Siu-Fun Wong, and her,colleagues, which concluded ... reduction in the pain and,itching of a rash ... as EGFR inhibitors. This ongoing supportive care trial ...
Cached Medicine Technology:Large Geographic Differences in EpiPen Prescriptions in the U.S.,From the Journal of Allergy and Clinical Immunology 2Clinical Study Shows Regenecare Relieves Pain and Itching of Skin,Rashes Caused by Widely Used Cancer Drugs 2
(Date:10/25/2014)... New York, New York (PRWEB) October 25, 2014 ... lawsuits ( http://www.thexareltolawsuit.com/ ) will be addressed in December, ... convenes its next hearing session. According to a Hearing ... Oral Arguments on the matter will be heard on ... Session will begin at 9:30 a.m. (In Re: Xarelto ...
(Date:10/25/2014)... Madison, WI (PRWEB) October 25, 2014 ... of tax-advantaged medical and other benefits account management ... designed to help employers save on taxes, reduce ... new Suites provide tax savings and the efficient ... can pick the Suite that best meets their ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 The ... ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston Scientific ... U.S. District Court, Southern District of West Virginia ... on Punitive Damages in a group of cases ... ruling issued on October 21st, U.S. District Judge ...
(Date:10/25/2014)... -- Not getting the right amount of sleep might ... suggests. Those who sleep less or more than ... be more prone to developing the chronic condition, which ... authors concluded that duration and quality of sleep are ... bowel diseases. "Both short and long durations of ...
(Date:10/25/2014)... 2014 (HealthDay News) -- October,s shorter, darker days can ... disorder, according to an expert. People affected ... overly tired, lack motivation and even have trouble getting ... to suicide, said Dr. Angelos Halaris, a professor in ... University Chicago Stitch School of Medicine. "Seasonal affective ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 3Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... Successful, OWINGS MILLS, Md., Oct. 4 Medifast, ... the current business outlook, the,Company is updating full year ... expects to report revenue of $81 to $83 million ... Previously, the Company,expected to report revenue of $85 to ...
... just part of what is ... local nonprofit for teens., WILSONVILLE, Ore., Oct. 4 On Tuesday, ... in furniture,arcade games and supplies. These and other items, unused for at ... to the,Sexual Minority Youth Resource Center (SMYRC). Volunteer crews will move ...
... - A new American Heart,Association survey (1) shows consumer awareness of the ... high. But consumers still need,some key information to improve how they eat., ... Fats Are The survey shows that:, --While 92 percent of ... jump from 84 percent in 2006 - only 21 percent can name ...
... revealing how toxic chemicals disrupt gene activity and other ... -- and why some individuals are particularly vulnerable. For ... more likely to experience side effects from certain medications, ... , How can this type of research -- known ...
... 22 new centers now added, first participants set to join ... -- The largest study ever of the impact of environment ... directed from 22 new centers across the United States, organizers ... first participants enrolled in the National Children,s Study should be ...
... president and CCO of,KickSkirt, Inc., will lead a ... the health of their children while also improving ... The Marketing-To-Moms Conference,October 23-24, 2007, Chicago Cultural Center. ... and medical director of Peak Wellness and star ...
Cached Medicine News:Health News:Medifast Announces Updated Full Year 2007 Guidance 2Health News:Medifast Announces Updated Full Year 2007 Guidance 3Health News:Medifast Announces Updated Full Year 2007 Guidance 4Health News:Contents of the McGinnis Mansion Refurbishes Portland, Oregon Sexual Minority Youth Center 2Health News:Contents of the McGinnis Mansion Refurbishes Portland, Oregon Sexual Minority Youth Center 3Health News:Americans' Knowledge of Fats Growing But Still Insufficient 2Health News:Americans' Knowledge of Fats Growing But Still Insufficient 3Health News:Largest Study of U.S. Children Readies for Launch 2Health News:Brands Tackle the Childhood Obesity Issue During M2Moms(TM) - The Marketing-To-Moms Conference 2
... lightweight self-adhesive insulin pod that you fill with ... up to three days and then replace. The ... your body through a small flexible tube (called ... into its wireless companion, the Personal Diabetes Manager. ...
The MiniMed Paradigm REAL-Time System is the world's first system to integrate an insulin pump with REAL-Time continuous glucose monitoring, taking diabetes management to a level you just can't achie...
The IR 1000 Insulin Infusion Pump from Animas offers unprecedented safety features, performance, and convenience....
... premium product for acne, XtremeClear, powered ... on a scalable multi-application platform. A ... acne, XtremeClear works fast, providing noticeable ... treatments. Uncompromising safety in each of ...
Medicine Products: